论文部分内容阅读
目的:观察健脾渗湿抑瘤法联合XELOX化疗治疗结肠癌脾虚湿蕴证的临床疗效。方法:将结肠癌根治术后患者60例随机分为2组,各30例;治疗组采用健脾渗湿抑瘤法联合XELOX化疗,对照组仅予XELOX化疗,每疗程21天,连续治疗4疗程;比较2组治疗前后患者生活质量评分(QOL)及毒副作用情况。结果:治疗后2组QOL评分均较治疗前明显升高(P<0.01),且治疗组QOL评分升高较对照组更显著(P<0.01)。治疗后治疗组骨髓抑制分度明显轻于对照组,经秩和检验,差异有统计学意义(P<0.05)。治疗后治疗组骨髓抑制分度轻于对照组,但经秩和检验,差异无统计学意义(P>0.05)。结论:健脾渗湿抑瘤法能有效改善结肠癌根治术后辅助化疗患者的生活质量,减轻化疗毒副作用,值得临床推广应用。
Objective: To observe the clinical efficacy of Jianpi Shenshi antitumor combined with XELOX chemotherapy in the treatment of colon and spleen deficiency syndrome. Methods: 60 cases of colon cancer after radical operation were randomly divided into two groups, 30 cases in each group. The treatment group was treated with invigorating the spleen and osmotic wetting combined with XELOX chemotherapy. The control group was given only XELOX chemotherapy for 21 days. The quality of life (QOL) and toxicity were compared between the two groups before and after treatment. Results: After treatment, the QOL scores in both groups were significantly higher than those before treatment (P <0.01), and the QOL scores in the treatment group were significantly higher than those in the control group (P <0.01). After treatment, the degree of myelosuppression in the treatment group was significantly lower than that in the control group. The rank sum test showed significant difference (P <0.05). After treatment, the degree of myelosuppression in treatment group was lower than that in control group, but there was no significant difference (P> 0.05) by rank sum test. Conclusion: The therapy of invigorating the spleen and osmosis and dampness and inhibiting the tumor can effectively improve the quality of life of adjuvant chemotherapy patients after radical resection of colon cancer and relieve the toxic and side effects of chemotherapy, which is worthy of clinical application.